Prudential Financial Inc. Has $986,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Prudential Financial Inc. lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,334 shares of the specialty pharmaceutical company’s stock after selling 367 shares during the period. Prudential Financial Inc.’s holdings in Collegium Pharmaceutical were worth $986,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. TD Private Client Wealth LLC grew its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. KBC Group NV grew its position in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock worth $196,000 after purchasing an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter worth about $230,000.

Collegium Pharmaceutical Stock Down 3.0 %

Shares of NASDAQ COLL opened at $28.14 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The firm’s 50-day simple moving average is $30.02 and its 200 day simple moving average is $32.11. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market cap of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company’s stock, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.